Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis |
| |
| Authors: | José de J. Guerrero-García Argelia E. Rojas-Mayorquín Yeminia Valle Jorge R. Padilla-Gutiérrez Víctor A. Castañeda-Moreno Mario A. Mireles-Ramírez José F. Muñoz-Valle Daniel Ortuño-Sahagún |
| |
| Affiliation: | 1. Instituto de Investigación en Ciencias Biomédicas (IICB), CUCS, Universidad de Guadalajara, Jalisco, Mexico;2. Unidad Médica de Alta Especialidad (UMAE), Hospital de Pediatría (HP), Centro Médico Nacional de Occidente (CMNO), IMSS, Mexico;3. Departamento de Ciencias Ambientales, Instituto de Neurociencias, CUCBA, Universidad de Guadalajara, Jalisco, Mexico;4. Unidad Médica de Alta Especialidad (UMAE), Hospital de Especialidades (HE), Centro Médico Nacional de Occidente (CMNO), IMSS, Mexico |
| |
| Abstract: | The CD40/CD40L system is a binding key for co-stimulation of immune cells. Soluble form of CD40L has been widely studied as marker of inflammatory and autoimmune diseases. Here we analyze serum concentrations of sCD40L, as well as 14 cytokines, in patients with Multiple Sclerosis (MS) treated with Glatiramer acetate or Interferon beta. In the healthy control group, we found in serum a highly positive correlation between sCD40L and Interleukin (IL)-31, an anti-inflammatory Th2 cytokine. Additionally, an important reduction in IL-31 and sCD40L serum levels, as well as a significant reduction in CD40 mRNA expression and complete depletion of CD40L mRNA, detected from peripheral blood cells, was found in treated patients with MS. Therefore, sCD40L and IL-31 must be taken into account as possible prognostic markers when analyzing the disease progress of MS in order to provide more personalized treatment. |
| |
| Keywords: | Multiple sclerosis sCD40L IL-31 Glatiramer acetate IFN-β |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
